In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma "may violate the procedural provisions" of the Hart-Scott-Rodino (HSR) Act.
<a href="https://www.fiercebiotech.com/biotech/ftc-tells-novo-its-metsera-offer-may-violate-us-merger-law-current-form" hreflang="en">FTC warns Novo that current Metsera offer structure may violate US merger law</a>
FierceBiotech | | Eric Sagonowsky
Topics: oncology